Abstract 5-Fluororaucil (5-FU) as anti-cancer drug was reported to induce thymidine synthase (TS) overexpression and cancer cell resistance. To improve its therapeutic efficacy and selective targeting, here we developed a targeted delivery system mediated by the active ligand-folate receptor chemistry to deliver the 5-FU drug selectively into the tumor microenvironment. The preparation was achieved by exploring chitosan (CS)-biopolymer based system with folic acid (FA)-conjugation. The 5-FU@FACS-Mn:ZnS quantum dots (QDs) based on the histological assessment conducted in the 4T1 challenged mice showed an improved tumor remission in the liver, spleen and lungs. The 5-FU@FACS-Mn:ZnS composite induced anti-proliferative properties in these organs as compared to the free 5-FU drug. Unlike the 5-FU@FACS-Mn:ZnS treated groups which showed some specific morphological changes such as cell shrinkage without obvious presence of adipocytes, the excised section of the tumor in the untreated control group and the free 5-FU drug treated group showed necrotic and degenerated cells; these cells are multifocally distributed in the tumor mass with evidence of widely distributed adipocytes within the tumor mass. These findings suggest that the 5-FU@FACS-Mn:ZnS composite has a superior role during the induction of apoptosis in the 4T1 cells as compared to the free 5-FU drug treated groups. The results of the study therefore suggest that the impregnation of 5-FU anti-cancer drug within the FACSMn:ZnS system significantly improves its selective targeting efficacy, in addition to improving the anti-proliferative properties and attenuate possible tumor resistances to the 5-FU drug.
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The work discusses about the antimetastatic effects of folic acid-bound 5-Fluororacil loaded Mn:ZnS quantum dots towards 4T1 cell line proliferation in mice based on the histological analysis.
Introduction
5-fluorouracil (5-FU) drug was designed to preferentially inhibit tumor growth by disrupting the normal nucleotidebinding sites of Thymidine synthase (TS) or disrupting the normal cell growth by impairing gene-encoding processes [1, 2] . In addition to this metabolic process, the cytotoxic activity of the 5-FU drug also exerts unspecific killing spree without recourse to the tumor and normal cells [3] . The greatest concern widely documented is the propensity of tumor cells resistance towards 5-FU, reported to exert onlỹ 10% response rate during the treatment of colorectal cancer with slight improvement to about~45% response rate in combination with other anti-cancer drugs [4] . A cited report shows that the continuous exposure of 5-FU induces TS overexpression, stimulating the cancer cell line resistance to the drug, thereby limiting its application in cancer treatment [5, 6] .
In recent years, a series of reports showed improved 5-FU efficacy through combination therapies with other anticancer drugs [2, [7] [8] [9] [10] . However, in combinatorial approaches, factors such as the difference in physicochemical and pharmacokinetic properties of the individual drugs may interfere with the therapeutic efficacy and physiological sensitivity, and therefore may end up inducing other rare side effects [11] . Su et al. [12] reported that the co-administration of multiple drugs induces multidrug resistance by the cancer cells which according to their findings could be ameliorated using nano-delivery approaches. Recognizing the above challenges involved in the combination-therapeutic approaches, the engineered nanomaterials with selective targeting characteristics are reported to be an effective approach towards improving the anticancer properties and selective bioavailability for the 5-FU drug [12] [13] [14] [15] [16] [17] .
Based on that, we synthesized a targeted system to improve the 5-FU anti-cancer drug by improving its bioavailability and selective tumor-targeting efficacy in the folate receptors (FRs) overexpressing cancer cells in vitro and in vivo. In the study, as presented in our earlier reports, we employed four sequential wet chemistry steps to prepare the FA-conjugated chitosan (CS)-based Mn:ZnS QDs system (FACS-Mn:ZnS) to deliver 5-FU drug to the cancer cells by following FA-FRs chemistry [18, 19] . The in vitro results from the study showed that the cancer cell lines (MCF-7 and MDA-MB231) treated with 5-FU@FACS-Mn: ZnS QDs induced an increase in the levels of apoptotic cells and tumor selectivity as against the pure 5-FU anti-cancer drug. In addition to the significant anti-cancer effects demonstrated by the 5-FU@FACS-Mn:ZnS in vitro, the drug loaded QDs were also effective towards reducing the tumor burden in vivo by inhibiting the tumor growth and suppressing the proliferating tendency of 4T1 cell lines invasion in the healthy normal cells [19] .
In the present study, we histologically determined the toxicity index in vivo and the therapeutic efficacy of the assynthesized 5-FU@FACS-Mn:ZnS composite towards inhibiting the proliferation of 4T1 cells in vivo. The study showed that, as compared to the free 5-FU drug, the 5-FU@FACS-Mn:ZnS composite markedly decreased tumor metastasis and associated pathology in the liver, spleen, kidney and lungs of the 4T1 cancer cell challenged mice. The results further showed that the 5-FU@FACS-Mn:ZnS system effectively supressed the expression of proinflammatory nitric oxide (NO) and malondialdehyde (MDA) activity levels in the 4T1 challenged mice in vivo.
Materials and methods

Chemicals
Low-molecular-weight chitosan (75-85% degree of deacetylation) was purchased from Sigma-Aldrich (St Louis, MO, USA), while the other chemicals such as ethanol (99.5%) were purchased from Fisher Scientific (Malaysia) and acetic acid (99.85%) from Benson Lab Chemicals (Malaysia). Zinc acetate dehydrate (Zn(CH 3 COO) 2 ⋅2H 2 O) 99.5%, FA (C 19 H 9 N 7 O 6 , 98%), sodium sulphide (Na 2 S⋅XH 2 O), manganese sulphate (MnSO 4 ⋅H 2 O, 99%), and sodium tripolyphosphate (Na 5 O 10 P 3 , 59%) were purchased from R&M Marketing (Essex, UK). 2,4-dihydroxy-5-fluorpyrimidin (5-FU) was purchased from Tokyo Chemical Industry Co. Ltd (Toshima, Tokyo, Japan). Deionized (DI) water was used across all treatments.
Synthesis of 5-FU loaded FACS-Mn:ZnS
The detailed procedure for the preparation of 5-FU@FACS-Mn:ZnS composite was presented in our previous study [19] . Briefly, the composite was synthesised by first preparing a stable FACS suspension and for that, about 2 mL of FA in DI water was added drop-wise to 5 mL of CS solution in dilute acetic acid under stirring followed by the drop-wise addition of 2 mL of TPP in DI water. To the FACS suspension, a colloidal solution of Mn:ZnS was added drop-wise under sonication and stirred for 1 h to form the FACS-Mn:ZnS nanoparticles (NPs) by subjecting the solution to centrifugation (Kubato 2100, Kubato corporation, Japan) at 4000 rpm for 10 min. The Mn:ZnS was synthesized by adding 1.5 mL of 15 at.% MnSO 4 to 10 mL of Zn(CH 3 COO) 2 solution under ultrasonication followed by stirring under nitrogen atmosphere for 15 min. To the precursor, 10 mL of Na 2 S solution was added drop-wise under stirring to form a white precipitate of Mn:ZnS.
Finally, the 5-FU@FACS-Mn:ZnS composite was prepared by dispersing the 5-FU anti-cancer drug in methanol to aqueous colloidal solution of FACS-Mn:ZnS under sonication followed by stirring at 4°C for 8 h. The 5-FU@FACS-Mn:ZnS composite was collated by centrifugation at 4000 rpm for 10 min.
Animal study and treatment
A total of forty-five (45) female Balb/c mice aged between 5 and 6 weeks old and weighing between 18 and 20 g obtained from Universiti Putra Malaysia (UPM) animal resource unit were used for this study. The mice were acclimatized for 2 weeks prior to the commencement of the experiment. The experiment was conducted in accordance with the regulations set by the UPM animal ethics committee's guidelines for the care of laboratory animals (IACUC approval RO53/2015). The mice were divided into two parts for the study, the sub-chronic toxicity study and the anti-cancer efficacy study groups. The sub-chronic toxicity study is made up of five groups consisting of five mice per group. After the acclimatization period, the mice in this study group were injected intraperitoneally based on the following groupings. Group I received 100 mL/kg of PBS (normal control), Groups II, III and IV received 4.8 mg/kg of Mn:ZnS, FACS-Mn:ZnS and 5-FU, respectively. However, the Group V mice were administered 8 mg/kg of 5-FU@FACS-Mn:ZnS NPs. The administration schedules was conducted for 28 days.
In the anti-cancer study, the mice were randomly divided into four groups consisting of five mice in each. After the acclimatization period, all mice were inoculated with 1 × 10 5 4T1 cells subcutaneously and the treatment was conducted thrice/week for four cycles. Group I received 100 mL/kg of PBS (positive control), Groups II and III received 4.8 mg/kg of Mn:ZnS and 5-FU, respectively, while Group IV mice were administered 8 mg/kg of 5-FU@FACS-Mn: ZnS, intraperitoneally.
At the end of treatment cycles, the mice were anesthetised and euthanized. The samples of liver, spleen, kidney, tumour and lung were collected in 10% buffered formalin for histological processing. The levels of NO in the harvested tumor were measured in accordance with the user guidelines in the Griess reagent kit (Sigma, USA). Using an 80 µm mesh-wire, a homogenized buffered-saline tumor tissue was obtained and centrifuged at 2000xg for 5 min at 4°C. Following the centrifugation, the collected supernatants were mixed with the required Griess reagent (1% sulphanilamide and 0.1% N-1-naphthylethylenediamine dihydrochloride in 2.5% polyphosphoric acid) and DI water. Following the mixing, the sample was incubated for 30 min and the absorbance was measured using the microplate reader (Bio-Tek instruments, Winooska, VT, USA) at 548 nm. Similarly, the lipid peroxidation levels were measured using MDA assay by thiobarbituric acid (TBA) reaction. The supernatant from the meshed tumor was collected and mixed with butylated hydroxytoluen (BHT) and further mixed with 2,4,6-Trichloroanisole (TCA), vortexed and incubated in ice for 2 h. Following the cooling, the mixtures were centrifuged and the collected supernatants were further mixed with TBA and build for 15 min. By making use of tetramethoxypropan as a standard, the absorbance of the mixture was measured using the spectrophotometer (Beackman Coulter, USA) at 532 nm wavelength.
The Haematoxylin and Eosin (H&E) staining was conducted by processing the fixed tissues, embedding in paraffin, sectioning and staining with Hematoxylin and Eosin. The slide was then examined under a bright-field microscope (Nikon, Japan) [20] .
Statistical analysis
The data was expressed as Mean ± SD of three individual experiments and the statistical analysis was conducted using Graph pad-prism software (version 6.0). One-way ANOVA and the student t-test were performed with the significance set at p < 0.05, highly significance set at p < 0.01, and very highly significance as p < 0.001.
Results
Morphology and particle size characterization
The high-resolution transmission electron microscopy (HRTEM) studies were recorded on a FEI Tecnai G2 F20 transmission electron microscope by dispersing the particles in water. The micrograph obtained from the HRTEM analysis ( Fig. 1) shows a nanocomposite (5-FU@FACS-Mn: ZnS NPs) with an average particle size distribution of 7.5-10 nm. The topography of the particles appeared dispersed and are spherical in shape.
In vivo toxicity evaluation
The in vivo sub-chronic toxicity evaluation of the excised tissue sections of the mice injected with the Mn:ZnS, FACS-Mn:ZnS and the 5-FU@FACS-Mn:ZnS NPs in Fig. 2b-d shows a normal kidney architecture and without obvious pathological lesions. However, the pure 5-FU drug treated group shown in Fig. 2e indicate the presence of some tubular degeneration and necrosis with leucocytic infiltration in the interstitium of the kidneys.
Furthermore, the histological assessment of the lungs as presented in Fig. 3 shows a normal alveoli architecture but with mild thickening of the alveolar interstitial wall due to the leucocytic infiltration in the mice treated with Mn:ZnS, FACS-Mn:ZnS and 5-FU@FACS-Mn:ZnS NPs respectively ( Fig. 3b-d) . However, in the pure 5-FU drug treated group (Fig. 3e) , a severe thickening of the alveolar interstitial wall was observed.
Unlike what was observed in the pure 5-FU anti-cancer drug treated group (Fig. 4e) where it shows mild presence of some neoplastic cells, the histological assessment of the mice treated with the Mn:ZnS (Fig. 4b) , FACS-Mn:ZnS (Fig. 4c ) and the 5-FU@FACS-Mn:ZnS NPs (Fig. 4d) treated groups following the sub-chronic toxicity study showed a normal splenic architecture with normal white and red pulp morphology.
Similarly, the histology of the liver for the mice groups treated with the Mn:ZnS, FACS-Mn:ZnS and the 5-FU@FACS-Mn:ZnS NPs did not show any obvious degeneration of the hepatocytes or liver damage Fig. 5b-d) . However, the 5-FU drug being widely degraded in the liver, induced some cloudy degeneration of the hepatocyte and necrosis (Fig. 5e ).
In vivo anti-cancer efficacy study
The anti-tumor efficacy of the 5-FU@FACS-Mn:ZnS nanocomposite was evaluated and measure against the efficacy of the pure 5-FU anti-cancer drugs. The study was conducted in 4T1 induced female Balb/c mice. The activities of endogenous species in the harvested tumor and their role toward the activation of inflammations and tumor signalling components were reported in Fig. 6 . The results shows a reduction in the activity levels of both NO and MDA in the groups treated with the pure 5-FU anti-cancer drugs and the 5-FU@FACS-Mn:ZnS NPs treated groups when compared to the untreated and the Mn:ZnS treated groups. In the same study, the results further shows that the treatment with the 5-FU@FACS-Mn:ZnS NPs significantly suppressed the expression of the endogenous species compared to the pure 5-FU anti-cancer treated groups.
In addition to the in vivo anti-cancer efficacy study based on the activity levels of NO and MDA in the harvested tumor, the histology (lungs, kidney, spleen, liver and tumor) of the mice inoculated with the 4T1 cancer cells were also investigated in order to understand the impact of the treatments toward suppressing the 4T1 cells proliferations.
The H&E photomicrographs of the lungs in both the untreated control group (Fig. 7a) and Mn:ZnS group (Fig.  7b ) of the 4T1 challenged mice showed evidence of extensive tumor metastasis with obvious thickening of the alveolar interstitial walls and obliteration of alveolar air spaces. Necrotic areas typified by dead cells were also observed in the lungs of untreated groups. Furthermore, the 5-FU treated group (Fig. 7c) showed a decrease in the number of metastasised cells, while the 5-FU@FACS-Mn: ZnS NPs treated group (Fig. 7d) showed a tremendous remission of the tumor and normalised alveolar interstitial walls.
Also, the photomicrographic images of the kidney in Fig.  8 shows that only the kidney in the untreated control group (Fig. 8a) showed evidence of cancer invasion, as it has a large metastatic tumor mass surrounded by a rich blood network alongside few degenerated and necrotic tubules. Although, there was no evidence of cancer metastasis in the Mn:ZnS QDs (Fig. 8b) and 5-FU (Fig. 8c ) treated groups; this group however shows presence of some tubular degeneration and necrosis with leucocytic infiltration in the interstitium.
The photomicrographs of the spleen with and without the treatment following 4T1 cells inoculation in mice is shown in Fig. 9a-d . From the figure, with the exception of 5-FU@FACS-Mn:ZnS NPs treated group (Fig. 9d) whose spleen showed an improved lymphocyte population in the white pulp and viable red pulp, the groups treated with the bare QDs (Fig. 9b) and 5-FU drug (Fig. 9c) showed a compromised spleen morphology with extensive depopulation of lymphocytes from the white pulp and no clear distinction or delineation between the white and red pulps.
The H & E photomicrographs of the liver revealed evidence of tumor metastasis around congested central veins in all the treatment groups, with the groups treated with the 5-FU and the 5-FU@FACS-Mn:ZnS showing less distribution of metastasized cells (Fig. 10) . A moderate result was observed for the 5-FU@FACS-Mn:ZnS NPs treated group (Fig. 10d) as compared to the pure 5-FU treated group (Fig. 10c) .
Histologically, the untreated groups, the QDs and the free 5-FU anti-cancer treated mice showed tumor mass that appeared diffusely populated with tumor cells (Fig. 11) . The tumor cells completely invaded the normal cells, which appeared to have lost their morphology. Necrotic and degenerate cells were observed to be multifocally distributed in the tumor mass with evidence of adipocytes which were observed to be widely distributed within the tumor mass. However, the 5-FU@FACS-Mn:ZnS NPs treated groups (Fig. 11d) showed some specific morphological changes such as cell shrinkage without obvious expression of adipocytes.
Discussion
Our earlier studies reports that both the drug free (FACSMn:ZnS) and the 5-FU loaded FACS-Mn:ZnS nanocomposite exerts insignificant cytotoxicity against normal breast line (MCF-10A) and breast cancer cell lines (MDA-MB231 and MCF-7) in vitro [18, 19] . Despite those encouraging in vitro results, it became imperative herewith to report further the in vivo toxicity findings in order to share more insight into the biosafety profile of the asprepared nanocomposites. For that, an in vivo histological assessment of the nanocomposite following the repeated administration was carried out. The in vivo sub-chronic study provides more information on the safety of using the FACS-Mn:ZnS NPs as a probe/carrier system for the targeted delivery applications with the sole aim of improving the anti-cancer efficacy of 5-FU drug, in addition to attenuating its non-specific toxic side effects and to enhance its bioavailability in vivo.
The preparation of the drug delivery device (FACS-Mn: ZnS) as a poly-dispersed system was to ensure efficient particle-cellular interactions, efficient blood circulation, bioavailability and in vivo biocompatibility. As demonstrated in Fig. 1 , the morphology and size distribution of the as-prepared 5-FU@FACS-Mn:ZnS nanocomposite despite the functionalization processes appears to be spherical in shape with a good particle size distribution. In our previous study, the crystallinity of the vector free nanocomposite shows a spectra pattern typical of ZnS in a cubic blend (sphalerite) structure with characteristics peaks at the 2θ value of 28.46°, 48.16°, and 55.28°corresponding to the prominent diffraction at (111), (220), and (311) respectively. The peaks were observed to be well pronounced in the entire spectra, indicating the persistence of crystallinity of ZnS in the preparation [18] .
The particles formation in the spherical shape offers good biocompatibility for the in vivo particle-cellular interactions needed for this study [21] [22] [23] [24] . For that, the vector free (FACS-Mn:ZnS), the drug loaded (5-FU@FACS-Mn:ZnS) nanocomposite, the pure anti-cancer drug (5-FU) as well as the fluorescent contrast agent (Mn: ZnS) were all investigated histologically in female Balb/c mice following the repeated intraperitoneal injection for 28 days. Based on the histological assessment conducted, the reticuloendothelial system (RES) examined in this study shows the groups treated with the QDs, FACS-Mn:ZnS and the 5-FU@FACS-Mn:ZnS nanocomposite showing only few hepatocytes undergoing some cloudy morphology and mild thickening of the alveolar interstitial wall of the lung due to leucocytic infiltration. These alterations did not generate any obvious morphological damage. In that way, the results suggest that the changes are response from some phagocytic processes that are necessary for the normal metabolic activity of the RES.
However, a different trend was observed in groups treated with the pure (5-FU) anti-cancer drug. The pure anticancer (5-FU) drug induces some tubular generation and necrosis in the kidney, severe thickening of the alveolar interstitial wall of the lungs was also observed. Other pathological lesion observed is the cloudy degeneration and necrosis of the hepatocytes. In general, the 5-FU drug primarily gets catabolized in the liver by the enzyme dihydropyrimidine dehydrogenase, thereby forming dihydrouracil which in its reduced form cleaves into α-fluoro-β-alanine, ammonia, urea, and carbon dioxide [25] . Based on the role played by the liver, the hepatocytes are the primary target of its toxicity. Furthermore, the kidney being the route for clearance is also prone to its rare side effects. Similarly, due to the gaseous exchange processes in the body, the 5-FU drug can easily trigger inflammatory responses within the alveolar walls of the lungs and interfere with the immune mechanism of the spleen. In addition, the 5-FU drug was also reported to exhibit some abnormal histological changes such as periportal fibrosis, degeneration of hepatic cords and increased apoptosis in the liver of male albino rats [25] . The pathological lesions such as vascular degeneration of the hepatocytes, loss of normal histological architecture of the liver, in addition to severe fatty changes and apoptosis of the hepatocytes were also reported following the intraperitoneal injection of the 5-FU drug in female rats [26] . Although, the toxicity of pure 5-FU drug observed in this study is not very severe, further suggests the need for improving its efficacy and reduce the toxicity index. However, from the histological studies so far, it is suffice to say that the as-synthesized FACS-Mn: ZnS nanocomposite as a drug carrier system demonstrated enough potentials towards attenuating the toxicity index of pure 5-FU drug.
Following the sub-chronic toxicity evaluation, further investigations were conducted on the groups of mice inoculated with 4T1 cancer cell lines in order to draw more impetus on the anti-cancer efficacy of the as-prepared 5-FU@FACS-Mn:ZnS NPs as compared to administering the pure 5-FU anti-cancer drug. In this study, a post-mortem histological analysis was carried out on the H&E tissue sections of the liver, spleen, lung, kidneys and the harvested tumor. Further biochemical analysis of the meshed tumor was used to measure the activity of proinflammatory component in the tumor bearing mice in relation to the impact of treatments. The proliferation rate and expression of important endogenous signalling components in mammalian cells were reported to be directly influenced by the cancer microenvironments [27, 28] . In this work, the activity levels of these endogenous signalling components in the tumor were investigated so as to understand the efficacy of the treatments towards reducing the tumor progression. The small proteins such as cytokines can activate the macrophagemediated mechanisms in order to induce the generation of endogenous gases such as nitric oxide (NO) by upregulating the expression of inducible nitrate oxide synthase (NOS2) isoform found in abundance in the breast cancer cells [29] [30] [31] [32] [33] . The NOS2 is a co-enzyme that catalyses the production of NO from L-arginine. The NOS2 activity in the tumour cells has been associated with the tumor proliferation and expression of receptor hormones (oestrogen), an important signalling component associated with the cancer development [28] . The NO readily reacts intracellularly and further induces the generation of nitrite, nitrate and peroxynitrite as the intracellular components. These metabolites play an active role in the oxidative degeneration of cell components and promoting genotoxic effects, thereby favouring cancer cell proliferation and tumor growth. Similarly, Malondialdehyde (MDA), an endogenous genotoxic product generated from the enzymatic or free radical-induced lipid peroxidation was also reported to have similar responses in the cancerous environment. The MDA generated from lipid peroxidation was detected to intracellularly react with the DNA to form MDA-DNA adducts which further plays a significant role as biomarkers for monitoring the endogenous DNA damage associated with the oxidative stress induced by the cancer microenvironment [34, 35] .
As observed in all the groups (Fig. 6 ), the 4T1 cell lines drastically increased the activity levels of both NO and MDA, thereby suggesting the possible induction of inflammation by the tumor cells. The 4T1 cancer cells used in this study are highly invasive and have the propensity of invading the nearby healthy cells. The binding affinity of the FA to the FRs expressed by the 4T1 cells is used as a trojan horse to deliver the anticancer drug (5-FU) and this is with a view that the 4T1 cells engulf the FA mediated by the FRs will be invariable in consuming more of the encapsulated 5-FU anticancer drug. The reduction of pro-inflammatory mediators such as the NO and MDA may render the cancer cells more susceptible to anticancer treatment. Thus, from the results, when compared to the untreated groups, the pure 5-FU treated groups were observed to have low activities in both the NO and MDA levels. Similarly, a significant (p < 0.001) reduction was also observed in the groups treated with 5-FU@FACS-Mn: ZnS NPs when compared to the pure 5-FU treated groups. From the overall results, the 5-FU@FACS-Mn:ZnS NPs significantly ameliorate the expression of both the NO and MDA activity levels as compared to the pure 5-FU drug. This suggests that the as-prepared 5-FU@FACS-Mn:ZnS nanocomposite was able to suppress the pro-inflammatory activity of both NO and MDA by inducing the higher antitumor efficacy better than the free 5-FU anti-cancer drug. These anti-inflammatory effects of the folate-drug conjugate could be further attributed to the FA-FRs mediation. The FA in its dietary form as 5-methyltetrahydrofolate [12] [13] [14] [15] [16] . The FdUMP exerts its effects by inhibiting the TS synthesis, thereby crippling the cancer cell proliferation by slowing down the expression of the proinflammatory agents (NO and MDA) respectively.
From the H&E staining, a vast necrotic areas typified by the dead cells were observed in the lungs of untreated groups and the group treated with only the Mn;ZnS QDs. Furthermore, following the treatment with the pure 5-FU anti-cancer drug, the severity of the number of metastasised cells in the lungs was observed to have decreased (Fig. 7c) . However, as compared to the pure 5-FU treated group, the 5-FU@FACS-Mn:ZnS NPs treated group showed a tremendous remission of the tumor and normalised alveolar interstitial walls (Fig. 7d) . These findings further suggest that the 5-FU@FACS-Mn:ZnS treatment was able to exert a superior tumor remission as compared to the pure 5-FU drug. The results further strengthen our previous investigations based on the clonogenic assay of the lungs, where the as-synthesized 5-FU@FACS-Mn:ZnS NPs was observed to significantly disrupt the proliferative property of the 4T1 cell lines in the tumor-bearing mice, as compared to the events induced by the free 5-FU drug [19] . In addition to the fluorescence imaging potential of the Mn:ZnS QDs as presented in our in vitro study [18] , the QDs deployed into the system was also used as a biomarker to measure the level of cellular uptake and bioaccumulation of the nanocomposite in vivo. The results provide additional impetus toward understanding the mediating role of FA-FRs chemistry in facilitating the cellular uptake of the nanocomposite. This was achieved by measuring the level of Zn (II) ion tissue biodistribution in vivo following ICPC analysis [19] . The result shows more Zn(II) ion concentration in the tumor of groups treated with the folate-QDs than in the groups treated with the non-folate QDs. Suggesting that the FA binding to the FRs expressed by the tumor cells facilitated the high Zn ion accumulation in the tumor of the folate-QDs groups. Given the conjugation of folate in the nanocomposite and the high level of Zn ion accumulation in the tumor, we assumed that the 5-FU@FACS-Mn:ZnS were taking-up into the 4T1 cells through FRs-mediated endocytosis, thus increasing the efficacy and cellular uptake of the anticancer drugs and in the process disrupts the growth and proliferation of the 4T1 cells.
The histology of the kidney shows a large metastatic tumor mass surrounded by rich blood network among the untreated control mice (Fig. 8a) . However, the other groups did not show evidence of cancer cells, only tubular degeneration and necrosis was observed in the kidney of this group (Figs. 8b-c) . Furthermore, due to the increased cellular uptake facilitated by the FA, the groups administered the folate loaded 5-FU nanocomposite shows a relatively healthier kidney, histologically showing a congested vessel without obvious degenerative or necrotic lesions (Fig. 8d) .
Further histological assessment of the spleen shows the white pulp completely depleted and infiltrated by the neoplastic cells in the untreated groups (Fig. 9a) , the bare QDs (Fig. 9b) and the pure 5-FU treated groups (Fig. 9c) respectively. This morphological alteration induced by the 4T1 cell line compromised the immunity cloud of the spleen, leaving the spleen defenceless, as the white pulp is physiologically involved in the recruitment of arsenal T-cells that helps in immune response. Consequently, the distorted red pulp compromised effective clearance by the macrophages. However, a different appraisal was histologically observed in the spleen of tumor bearing mice treated with the 5-FU@FACS-Mn:ZnS NPs. The spleen showed an improved lymphocyte population in the white pulp and viable red pulp (Fig. 9d) . This therefore suggests that the higher uptake of the 5-FU drug initiated by the FA-FRs chemistry in this group (5-FU@FACs-Mn:ZnS) gave the spleen enough energy to fight against the 4T1 cancer cells invasion.
Despite the role played by the liver in the metabolism of 5-FU, the 4T1 cell lines succeeded in invading the liver and surrounded the central vain (Fig. 10) . This further shows the invasiveness of the 4T1 cells and its doggedness towards evading the treatment. However, despite the invasion, the groups treated with the 5-FU@FACS-Mn:ZnS NPs (Fig.  10d) shows greater remission when compared to the pure 5-FU treated groups (Fig. 10c) . The observation therefore suggests that the proliferation of 4T1 cells across the liver are relatively disrupted by the drug loaded folate nanocomposite.
In the H & E section of the tumor, all the groups showed widespread necrosis and degenerated hepatocytes that appeared to be multifocally distributed in the tumor mass (Fig. 11 ). However, with the exception of the groups treated with the 5-FU@FACS-Mn:ZnS nanocomposite (Fig. 11d) showing less expression of fatty cells, all the remaining treatments shows a wide spread mass of adipocytes (Figs. 11a-c) . Adipocyte is a specialized fat cell that synthesizes and stores neutral fats in the breast cancer stroma [36] . The adipocytes can actively interact and modulate the cancer chemistry, thus facilitating the tumor growth, proliferation and therapy resistance [37, 38] . The observation of less expression of adipocytes in the tumor microenvironment of 5-FU@FACS-Mn:ZnS treated mice (Fig. 11d) further suggests that the folate-5-FU conjugates depleted the energy storage capability of the tumor cells by reducing the expression of adipocytes thereby fostering the cell death within the tumor compartment. Further comparison of the histological results within the groups, the recession in tumor groups were also seems to be favoured due to the reduction in both NO and MDA activity levels recorded in the 5-FU@FACS-Mn:ZnS treated groups (Fig. 6 ).
Conclusion
Cumulatively, from the histological examination, the 4T1 cells significantly affected the architecture of the RES organs by causing lymphocyte depletion and adversely affecting the normal metabolic functions of both the kidney and liver. Equally, we also observed that the treatment of 5-FU@FACS-Mn:ZnS NPs significantly lowered the proliferative tendency of 4T1 cells in the inoculated mice and maintained the normal integrity of the RES as evidenced by the reduced proliferative effects of the 4T1 cells. Moreover, the results suggest that the 5-FU@FACS-Mn: ZnS NPs owing to its targeting specificity, also able to enhance the cellular uptake of the drug conjugates by the cancer cells. Hence the drug-loaded conjugate was able to supress the proliferative tendency of 4T1 cells from dominating the entire RES by disrupting their growth rate. Finally, we indicate that the 5-FU@FACS-Mn:ZnS NPs due to their inbuilt characteristics such as fluorescence nature, biocompatibility, efficient drug loading, controlled drug release behaviour, targeted tumor, and cancer cell specific activity, the composite can have potential applications as probes for the simultaneous diagnosis and treatment of cancer.
